DICE Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DICE research report →
Range $60 – $60
Price Chart
About the company
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics.
- CEO
- J. Kevin Judice
- IPO
- 2021
- Employees
- 71
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on DICE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.27B
- P/E
- -22.97
- PEG
- -0.64
- P/S
- 0.00
- P/B
- -9.99
- EV/EBITDA
- -22.56
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 56.07%
- ROIC
- -14.80%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-88,221,000
- Net Income
- $-81,664,000-68.5%
- EPS
- $-2.07+47.1%
- OCF Growth
- -63.7%
- FCF Growth
- -66.4%
- 52W High
- $47.90
- 52W Low
- $15.08
- 50D MA
- $42.26
- 200D MA
- $34.24
- Beta
- 0.00
- RSI (14)
- 78
- Avg Volume
- 1.75M
No earnings-call transcripts are available for DICE yet.
- Free Float
- 0.0%
- Shares Outstanding
- 47.76M
- Float Shares
- 0
of shares held by institutions
118 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pictet Asset Management SA | 17.57K | ▲ 17.57K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 21,250 |
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | other | 786,407 |
| Aug 9, 23 | TETLOW SHARON | sell | 21,250 |
| Aug 9, 23 | TETLOW SHARON | sell | 49,841 |
| Aug 9, 23 | TETLOW SHARON | sell | 13,800 |
| Aug 9, 23 | Simson Jake | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 13,800 |
| Aug 9, 23 | Scopa James Paul | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 25,722 |
| Aug 9, 23 | Robertson Scott M. | sell | 56,920 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DICE coverage
Recent articles, reports, and earnings notes.
No research on DICE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DICE report →Novel ETFs: New Milestones for Crypto, Leverage, & Sports
etftrends.com · Oct 15
Novel ETFs: New Strategies Push Boundaries
etftrends.com · Sep 17
Lilly Completes Acquisition of DICE Therapeutics
prnewswire.com · Aug 9
Lilly Announces Extension of Tender Offer to Acquire DICE
prnewswire.com · Jul 25
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
marketwatch.com · Jul 12
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
businesswire.com · Jul 10
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly
zacks.com · Jun 21
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
zacks.com · Jun 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.